Paolo Gresele, Giacomo Rimatori, Luigi De Marco,Zaverio Ruggeri
The cell therapies are the new frontier of medicine. In this scenario, despite of having a great potential, the blood platelets have not clinically been exploited yet.Plasfer, unique in the world, have developed a complex method for the loading of platelets with drugs. The Plasfer method is fast, scalable, and automated.The company is now working on the clinical use of platelet concentrates intravenously infused in the patient for the treatment of advanced solid tumors, such as Glioblastoma an aggressive brain cancer.Moreover, the company is developing other programs: in the vaccine therapy using the platelets as antigen-presenting cells and in aesthetic/regenerative medicine where the platelets are already used.The Plasfer method is patented in Italy in 2014 .At the moment, Plasfer has three academic partnerships: University of Perugia, Centro Oncologico CRO FVG di Aviano (PN), and Amsterdam University Medical Center.
Info that pertains to enterprises and is displayed on this page is not to be read as a solicitation to invest -either directly or indirectly - in said enterprises. Any kind of decision that involves the possibility to be part of the firm's equity is to be read as taken independently from both suggestions and evaluations - either direct or indirect - made by UniCredit.